Journal of Neurology

, Volume 259, Issue 5, pp 855–861

Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis

  • M. B. D’hooghe
  • P. Haentjens
  • G. Nagels
  • T. D’Hooghe
  • J. De Keyser
Original Communication


Female gender and hormones have been associated with disease activity in multiple sclerosis (MS). We investigated age at menarche, use of oral contraceptives and pregnancy in relation to progression of disability in relapsing onset and progressive onset MS. We conducted a cross-sectional survey among individuals with MS, registered by the Flemish MS Society in Belgium. A time-to-event analysis and Cox proportional hazard regression were performed with time to Expanded Disability Status Score (EDSS) of 6 (requires a cane) as outcome measure. Hazard ratios for the time from onset and the time from birth were adjusted for age at onset and immunomodulatory treatment. Data on 973 women with definite MS were collected. In the relapsing onset group, women with at least two pregnancies had a reduced risk to reach EDSS 6 compared with nulliparous women. In the progressive onset group, later age at menarche was associated with a reduced risk to reach EDSS 6, whereas oral contraceptive use was associated with a higher risk of reaching EDSS 6. Our study corroborates the association of pregnancies with a reduced progression of disability in relapsing onset MS. In progressive onset MS, a slower progression was found in women with a later onset of menarche and a more rapid progression occurred when women reported the use of oral contraceptives.


Multiple sclerosis Female Pregnancy Menarche Oral contraceptives 


  1. 1.
    Alonso A, Hernan MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71(2):129–135. doi:10.1212/01.wnl.0000316802.35974.34 PubMedCrossRefGoogle Scholar
  2. 2.
    Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC (2006) Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5(11):932–936. doi:10.1016/S1474-4422(06)70581-6 PubMedCrossRefGoogle Scholar
  3. 3.
    Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dyment DA, Orton SM, Yee IM, Ebers GC, Sadovnick AD (2009) Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol 16(3):342–347. doi:10.1111/j.1468-1331.2008.02431.x PubMedCrossRefGoogle Scholar
  4. 4.
    Sloka JS, Pryse-Phillips WE, Stefanelli M (2006) The relation between menarche and the age of first symptoms in a multiple sclerosis cohort. Mult Scler 12(3):333–339PubMedCrossRefGoogle Scholar
  5. 5.
    Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J (2006) Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 54(2):149–153. doi:10.1016/j.maturitas.2005.10.003 PubMedCrossRefGoogle Scholar
  6. 6.
    Poser S, Raun NE, Wikstrom J, Poser W (1979) Pregnancy, oral contraceptives and multiple sclerosis. Acta Neurol Scand 59(2–3):108–118PubMedGoogle Scholar
  7. 7.
    Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J (2010) Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril 10.1016/j.fertnstert.2010.06.045Google Scholar
  8. 8.
    Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339(5):285–291. doi:10.1056/NEJM199807303390501 PubMedCrossRefGoogle Scholar
  9. 9.
    Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, Voskuhl RR (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52(4):421–428. doi:10.1002/ana.10301 PubMedCrossRefGoogle Scholar
  10. 10.
    Runmarker B, Andersen O (1995) Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118(Pt 1):253–261PubMedCrossRefGoogle Scholar
  11. 11.
    D’Hooghe MB, Nagels G, Uitdehaag BM (2010) Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 81(1):38–41. doi:10.1136/jnnp.2008.163816 PubMedCrossRefGoogle Scholar
  12. 12.
    Koch M, Uyttenboogaart M, Heersema D, Steen C, De Keyser J (2009) Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 80(6):676–678. doi:10.1136/jnnp.2008.160911 PubMedCrossRefGoogle Scholar
  13. 13.
    Lisak RP (2007) Neurodegeneration in multiple sclerosis: defining the problem. Neurology 68(22 Suppl 3):S5–12. doi:10.1212/ (discussion S43-54)Google Scholar
  14. 14.
    Wilkins A, Scolding N (2008) Protecting axons in multiple sclerosis. Mult Scler 14(8):1013–1025. doi:10.1177/1352458508091370 PubMedCrossRefGoogle Scholar
  15. 15.
    Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, McDonald WI (1990) Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 300(6725):631–634PubMedCrossRefGoogle Scholar
  16. 16.
    van Ooteghem P, D’Hooghe MB, Vlietinck R, Carton H (1994) Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology 13(5):220–225PubMedCrossRefGoogle Scholar
  17. 17.
    Kobelt G (2006) Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 7(Suppl 2):S24–S33. doi:10.1007/s10198-006-0377-7 PubMedGoogle Scholar
  18. 18.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452PubMedCrossRefGoogle Scholar
  19. 19.
    Hohol MJ, Orav EJ, Weiner HL (1999) Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 5(5):349–354PubMedGoogle Scholar
  20. 20.
    Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R (1993) Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry 56(10):1062–1065PubMedCrossRefGoogle Scholar
  21. 21.
    Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW, Weiss S (2007) White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 27(8):1812–1823. doi:10.1523/JNEUROSCI.4441-06.2007 PubMedCrossRefGoogle Scholar
  22. 22.
    Blakemore SJ, Burnett S, Dahl RE (2010) The role of puberty in the developing adolescent brain. Hum Brain Mapp 31(6):926–933. doi:10.1002/hbm.21052 PubMedCrossRefGoogle Scholar
  23. 23.
    Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, Paus T, Evans AC, Rapoport JL (1999) Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 2(10):861–863. doi:10.1038/13158 PubMedCrossRefGoogle Scholar
  24. 24.
    Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Blumenfeld Z (2007) The neuroprotective effect of activin A and B: implication for neurodegenerative diseases. J Neurochem 103(3):962–971. doi:10.1111/j.1471-4159.2007.04785.x PubMedCrossRefGoogle Scholar
  25. 25.
    Bentzen J, Flachs EM, Stenager E, Bronnum-Hansen H, Koch-Henriksen N (2010) Prevalence of multiple sclerosis in Denmark 1950–2005. Mult Scler 16(5):520–525. doi:10.1177/1352458510364197 PubMedCrossRefGoogle Scholar
  26. 26.
    Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T (2007) Validation of the NARCOMS registry: diagnosis. Mult Scler 13(6):770–775. doi:10.1177/1352458506075031 PubMedCrossRefGoogle Scholar
  27. 27.
    Bowen J, Gibbons L, Gianas A, Kraft GH (2001) Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler 7(3):201–206PubMedGoogle Scholar
  28. 28.
    Ingram G, Colley E, Ben-Shlomo Y, Cossburn M, Hirst CL, Pickersgill TP, Robertson NP (2010) Validity of patient-derived disability and clinical data in multiple sclerosis. Mult Scler 16(4):472–479. doi:10.1177/1352458509358902 PubMedCrossRefGoogle Scholar
  29. 29.
    Must A, Phillips SM, Naumova EN, Blum M, Harris S, Dawson-Hughes B, Rand WM (2002) Recall of early menstrual history and menarcheal body size: after 30 years, how well do women remember? Am J Epidemiol 155(7):672–679PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. B. D’hooghe
    • 1
  • P. Haentjens
    • 2
  • G. Nagels
    • 1
    • 3
  • T. D’Hooghe
    • 4
  • J. De Keyser
    • 5
    • 6
  1. 1.National MS Center MelsbroekMelsbroekBelgium
  2. 2.Center of Outcomes Research, UZ BrusselVrije Universiteit BrusselBrusselBelgium
  3. 3.Department of Orthopedagogics, Faculty of Psychology and Education SciencesUniversity of MonsMonsBelgium
  4. 4.Leuven Fertility CenterDepartment of Obstetrics and GynecologyLeuvenBelgium
  5. 5.Department of Neurology UZ BrusselVrije Universiteit BrusselBrusselsBelgium
  6. 6.Department of NeurologyUniversity Medical Center GroningenGroningenThe Netherlands

Personalised recommendations